(NASDAQ: NXTC) Nextcure's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.23%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.87%.
Nextcure's earnings in 2025 is -$49,523,000.On average, 3 Wall Street analysts forecast NXTC's earnings for 2025 to be -$36,434,145, with the lowest NXTC earnings forecast at -$55,001,728, and the highest NXTC earnings forecast at -$15,708,101. On average, 3 Wall Street analysts forecast NXTC's earnings for 2026 to be -$28,237,181, with the lowest NXTC earnings forecast at -$42,145,395, and the highest NXTC earnings forecast at -$2,828,393.
In 2027, NXTC is forecast to generate -$1,823,262 in earnings, with the lowest earnings forecast at -$1,823,262 and the highest earnings forecast at -$1,823,262.